Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing

What this Trial Is About

Lymphoma, including large B-cell lymphoma (LBCL), is a common aggressive cancer affecting the lymphatic system. This research is focused on using a new method called phased variant analysis with next-generation sequencing to monitor circulating tumor DNA (ctDNA) in the blood. This approach aims to better understand how the lymphoma responds to treatment and to predict if the disease might come back, offering a potentially safer alternative to current imaging methods like CT and PET scans. The study is observational and involves collecting blood samples from participants diagnosed with lymphoma to analyze ctDNA using phased variant techniques. This advanced genetic testing looks at specific DNA mutations from tumor cells to track changes during treatment. The goal is to see how ctDNA levels correlate with early treatment outcomes over a period of up to 24 months or until death. Participants will be monitored through regular blood tests to measure ctDNA levels, alongside standard clinical assessments. Researchers will compare these results with disease progress and treatment response using clinical data. The main outcome measured is the relationship between ctDNA analyzed by phased variant and the early outcomes of lymphoma, helping to evaluate the effectiveness of this diagnostic approach while ensuring participant safety throughout the study duration.

Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing